Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Out-Licenses China CTLA-4 Rights to Hengrui in $200 Million Deal

publication date: Nov 22, 2021

Suzhou CStone Pharma out-licensed greater China rights for its CTLA-4 mAb to Jiangsu Hengrui Pharma in a $200 million agreement. Hengrui will have rights to develop, manufacture and commercialize CS1002 in the territories. CStone has completed a successful China Phase I trial of CS1002 in combination with its PD-1 that enrolled patients with melanoma, hepatocellular carcinoma and microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) tumors. The company will receive up to $200 million in upfront and milestone payments, plus double-digit royalties from Hengrui. More details....

Stock Symbols:  (HK: 2616) (SHA: 600276)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here